Clinuvel Pharmaceuticals Limited
CLVLF
$7.96
-$0.1583-1.95%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.93% | 10.89% | 9.61% | 9.34% | 10.29% |
| Total Other Revenue | 1.07% | 6.01% | 10.32% | 13.93% | 19.09% |
| Total Revenue | 10.10% | 10.49% | 9.67% | 9.70% | 10.99% |
| Cost of Revenue | 23.06% | 11.65% | 0.24% | -6.23% | -11.73% |
| Gross Profit | 8.94% | 10.37% | 10.67% | 11.46% | 13.60% |
| SG&A Expenses | -8.27% | 2.84% | 14.37% | 22.10% | 32.23% |
| Depreciation & Amortization | 18.25% | 29.24% | 40.91% | 33.62% | 27.22% |
| Other Operating Expenses | -2,201.86% | -2,201.86% | -2,201.86% | -125.58% | 89.68% |
| Total Operating Expenses | 4.70% | 9.26% | 12.80% | 16.27% | 21.31% |
| Operating Income | 14.75% | 11.50% | 7.25% | 4.74% | 3.39% |
| Income Before Tax | 24.52% | 17.02% | 8.33% | 7.75% | 8.49% |
| Income Tax Expenses | 19.77% | 9.51% | -2.17% | 1.73% | 7.20% |
| Earnings from Continuing Operations | 26.98% | 20.82% | 13.48% | 10.81% | 9.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.98% | 20.82% | 13.48% | 10.81% | 9.18% |
| EBIT | 14.75% | 11.50% | 7.25% | 4.74% | 3.39% |
| EBITDA | 14.99% | 11.98% | 7.94% | 5.27% | 3.76% |
| EPS Basic | 25.36% | 19.37% | 12.27% | 10.13% | 9.09% |
| Normalized Basic EPS | 22.91% | 15.65% | 7.18% | 7.12% | 8.41% |
| EPS Diluted | 30.27% | 23.58% | 15.65% | 12.22% | 9.70% |
| Normalized Diluted EPS | 27.93% | 19.89% | 10.55% | 9.08% | 8.87% |
| Average Basic Shares Outstanding | 1.24% | 1.05% | 0.86% | 0.50% | 0.14% |
| Average Diluted Shares Outstanding | -2.63% | -2.07% | -1.52% | -0.94% | -0.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.19% | -0.07% | 0.07% | 0.10% | 0.11% |